COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,388 Articles (22,816 medRxiv, 8,572 bioRxiv)

Most recent first Previous |  Page 2813: Articles 28121-28130  | Next

The characteristics and death risk factors of 132 COVID-19 pneumonia patients with comorbidities: a retrospective single center analysis in Wuhan, China
Chen, C., Yi, Z. J., Chang, L., Shuo, H. Z., Ming, Z., Pei, T., Lei, L., Xia, Z. W.
10.1101/2020.05.07.20092882 — Posted: 2020-05-12
Strong Effects of Population Density and Social Characteristics on Distribution of COVID-19 Infections in the United States
Rajan, K., Dhana, K., Barnes, L. L., Aggarwal, N. T., Evans, L., Wilson, R. S., Weuve, J., Evans, D. A.
10.1101/2020.05.08.20073239 — Posted: 2020-05-12
Pre-Procedural Surveillance Testing for SARS-CoV-2 in an Asymptomatic Population Shows Low Rates of Positivity
Mays, J. A., Greninger, A. L., Jerome, K. R., Lynch, J. B., Mathias, P. C.
10.1101/2020.05.08.20078592 — Posted: 2020-05-12
Evolving Transmission Network Dynamics of COVID-19 Cluster Infections in South Korea: a descriptive study
Kim, Y., Jiang, X.
10.1101/2020.05.07.20091769 — Posted: 2020-05-12
SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant
Konno, Y., Kimura, I., Uriu, K., Fukushi, M., Irie, T., Koyanagi, Y., Nakagawa, S., Sato, K.
10.1101/2020.05.11.088179 — Posted: 2020-05-12 Discussion: Onsite | Offsite
Predicting the Growth and Trend of COVID-19 Pandemic using Machine Learning and Cloud Computing
Tuli, S., Tuli, S., Tuli, R., Gill, S. S.
10.1101/2020.05.06.20091900 — Posted: 2020-05-11
Drive-through testing for SARS-CoV-2 in symptomatic health and social care workers and household members: an observational cohort study in Tayside, Scotland
Parcell, B., Brechin, K., Allstaff, S., Park, M., Third, W., Bean, S., Hind, C., Farmer, R., Chalmers, J. D.
10.1101/2020.05.08.20078386 — Posted: 2020-05-11
Structural insight into the putative role of Novel Coronavirus-2 E protein in viral infection via in silico approach: a potential target for LAV development and other therapeutic strategies
Sarkar, M., Saha, S.
10.1101/2020.05.11.088781 — Posted: 2020-05-11
Evidence for strong mutation bias towards, and selection against, T/U content in SARS-CoV2: implications for attenuated vaccine design.
Rice, A. M., Castillo Morales, A., Ho, A. T., Mordstein, C., Mühlhausen, S., Watson, S., Cano, L., Young, B., Kudla, G., Hurst, L. D.
10.1101/2020.05.11.088112 — Posted: 2020-05-11
Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model
Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Abbott, R. K., Callaghan, S., Garcia, E., He, W.-t., Hurtado, J., Limbo, O., Parren, M., Peng, L., Ricketts, J., Ricciardi, M. K., Smith, C., Song, G., Woehl, J., Yang, L., Rawlings, S., Smith, D. M., Nemazee, D., Teijaro, J. R., Voss, J. E., Andrabi, R., Briney, B., Landais, E., Sok, D., Jardine, J. G., Burton, D.
10.1101/2020.05.11.088674 — Posted: 2020-05-11 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).